Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

Abstract

Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among hepatitis C virus (HCV)-infected patients who also had other comorbid conditions. Materials & methods: The data was examined based on a variety of categories, encompassing age, gender, liver function enzymes, tumor markers and comorbid conditions. Results: In conclusion, DAAs demonstrated relatively effective results in HCV/hepatitis B virus coinfected patients, with a 78.2% sustained virological response rate, and 55.5% among HCV monoinfected patients in our study sample. However, some challenges remain, as we observed certain adverse effects associated with DAAs. Conclusion: In the past, interferon-based treatment regimens were the primary options against HCV; however, their limited success led to the development of DAAs drugs that reportedly cause adverse outcomes occasionally.